Startup profile · funding coverage
Inductive Bio
Collaborative AI platform accelerating small-molecule optimization via virtual chemistry labs.
Stage
series a
Status
private
Coverage
full
Why Inductive Bio is interesting
Won consecutive OpenADMET blind benchmarks; pre-competitive data consortium across pharma partners.
Key facts
- Investor: Andreessen Horowitz (a16z)
- Source: a16z public investment list / related coverage
- Seed (2023): $4.3M co-led by a16z Bio + Health and Lux; Bessemer participated (PR Newswire)
- Series A (2025): $25M led by Obvious Ventures; a16z Bio + Health and Lux re-upped (company blog)
Investors in our directory
Funds linked from Inductive Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Inductive Bio
Funding context and why this company shows up in venture coverage.
Inductive Bio builds a collaborative AI platform that accelerates small-molecule drug optimization through virtual chemistry labs.
Andreessen Horowitz (see /fund/andreessen-horowitz), Lux Capital (/fund/lux-capital), and Bessemer Venture Partners (/fund/bessemer-venture-partners) backed early rounds.
Inductive Bio raised a $4.3M seed in 2023 and a $25M Series A in 2025 led by Obvious Ventures (not in VCT directory).
Drug discovery still relies on slow iteration; Inductive Bio won consecutive OpenADMET blind benchmarks and runs a pre-competitive pharma data consortium.
Inductive Bio remains private as of July 2026.
Last updated: 2026-07-24